html">http://www.marketsandmarkets.com/Market-Reports/acute-myeloid-leukemia-therapeutics-market-526.html ] in G8 countries was valued at $216 million in 2010 and is expected to grow at a CAGR of 28.40% from 2015 to 2020. The market was dominated by AVD regimen in 2010. AVD regimen accounted for the largest share; i.e. 54.08% of the acute myeloid leukemia therapeutics market in G8 Countries in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cytarabine drug and Quizartinib molecule, with sales amounting to $698 million, $285 million, and $234 million respectively.
According to WHO, acute myeloid leukemia is expected to be more prominent in the developed world due to genetic and environmental factor, and radiation exposure is the primary cause of all the types of acute myeloid leukemia. Global incidence of acute myeloid leukemia was 49,539 in 2008 with the developing countries. Total 62,226 new cases were recorded in 2010 with 95,211 and 129,837 as the predicted new cases for 2015 and 2020.
The U.S. dominates the leukemia drug market in North America with a 90.19% share; whereas Germany dominates the market of Europe with 35.04% share.
The major players in the market include Ambit Biosciences Corporation (U.S.), Celgene Corporation (U.S.), Cephalon Inc. (U.S.), Clavis Pharma ASA (Norway), Eisai Co. Ltd (Japan), Genzyme Corporation (U.S.), and Sunesis Pharmaceuticals Inc. (U.S.).
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotePage: 1 2 3 Related biology technology :1
. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 20142
. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 20143
. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 20144
. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 20145
. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 20146
. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 20147
. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 20158
. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 20209
. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 202010
. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 202011
. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020